in-PharmaTechnologist presents a roundup of recent ingredient and formulation research, including improved API impurity detection and a simple step to boost stability.
The generic drug industry and the US FDA have reached an agreement that would see the former fund the latter’s overseas facility inspection programme to the tune of $299m a year, according to a number of reports.
Encap Drug Delivery now offers a ‘feasibility package’ to assess the potential of its Phoral coating technology as a vehicle for therapy in colonic diseases.
International Chemical Investors Group (ICIG) will take over Roche’s Colorado API plant in a bid to gain footing in the peptide manufacturing industry.
The final results of the US FDA, EMA, TGA joint manufacturing facility inspection programme will make for interesting reading for API producers as they strongly hint the approach is here to stay.
The EDQM has suggested Google Earth as a potential source of GPS co-ordinate data for manufacturing sites that must be supplied in CEP applications under recently introduced requirements.
Researchers at Alexandria University believe they can solve problems in the delivery of erectile dysfunction medication with the help of nanotechnology.
CMO Angel Biotechnologies has called in UK-based engineering group WH Partnership to help re-commissioning its GMP standard biomanufacturing facility in Cramlington near Newcastle-upon-Tyne.
India’s CDSCO has issued draft guidance designed to help active pharmaceutical ingredient (API) importers streamline the submission and registration process.
Researchers at the Georgia Institute of Technology have pioneered a multi-compartment gel capsule that could be used to simultaneously deliver drugs of different types.
Scientists at the University of British Columbia have pioneered a magnetic retinal implant that can supply a regulated and on-demand release of drugs to treat blindness from diabetic retinopathy.
Prosonix has secured funding to move its pipeline of proprietary mono and multi-component combination respiratory therapies through clinical development.
US stem-cell therapy firm NeoStem predicts that output of its China-based generic antibiotics subsidiary Suzhou Erye Pharmaceutical will increase after further manufacturing approval from the SFDA.
US drugmaker Baxter International has been ordered to pay compensation of $625,000 to the estate of man who received a dose of heparin that was contaminated with over-sulfated chondroitin sulphate (OSCS).
Switzerland-based life sciences supplier Lonza says it will invest CHF10m (€8m) to expand a Singapore plant that is part of its custom biomanufacturing business.
Ashland will buy International Specialty Products (ISP) in a deal designed to expand it's business in less cyclical, high-growth markets such as pharmaceuticals and personal care.
From July the EC will require that gelatin used in parenteral drugs is sourced from countries in World Organisation for Animal Health's (OIE) lowest risk categories for bovine spongiform encephalopathy (BSE).
German transdermal drug developer, Labtec, has opened what it claims is Europe’s most modern manufacturing facility for the production of transdermal drug delivery systems (TDS) and oral dispersible films (ODF) using its proprietary RapidFilm technology.
PolyPid claims its new polymer-lipid combination delivery tech will let pharmas set precise release characteristics for a variety of small molecule, protein and nucleic acid-base drugs.
Florida-based contract manufacturing organisation (CMO), Goodwin Biotechnology (GBI), has entered into an agreement with protein and monoclonal antibody drug developer, Rafagen, to provide cell line engineering and biological contract manufacturing services.